Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
-1.72 (-4.84%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.08 - 35.65
52 week 28.26 - 45.45
Open 35.24
Vol / Avg. 1.45M/875,751.00
Mkt cap 1.49B
P/E 82.04
Div/yield     -
EPS 0.41
Shares 41.22M
Beta 1.39
Inst. own 109%
May 4, 2015
Q1 2015 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 11, 2015
Acorda Therapeutics Inc at Barclays Healthcare Conference - 1:35PM EDT - Add to calendar
Mar 2, 2015
Acorda Therapeutics Inc at Cowen Health Care Conference - 2:10PM EST - Add to calendar
Feb 24, 2015
Acorda Therapeutics Inc at RBC Healthcare Conference
Feb 12, 2015
Acorda Therapeutics Inc at Leerink Global Healthcare Conference - Webcast
Feb 12, 2015
Q4 2014 Acorda Therapeutics Inc Earnings Release
Feb 12, 2015
Q4 2014 Acorda Therapeutics Inc Earnings Call
Feb 10, 2015
Acorda Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 12, 2015
Acorda Therapeutics Inc at JPMorgan Healthcare Conference
Dec 2, 2014
Acorda Therapeutics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 0.28% 4.40%
Operating margin 0.99% 9.06%
EBITD margin - 10.81%
Return on average assets 0.13% 2.09%
Return on average equity 0.25% 3.60%
Employees 421 -
CDP Score - -


420 Saw Mill River Road
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acorda Therapeutics, Inc. (Acorda) is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The Company�s Ampyra (dalfampridine) is used as a treatment to improve walking in patients with MS. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride. The Company is developing six clinical-stage therapies and one pre-clinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. It is also developing Plumiaz (trade name for Diazepam Nasal Spray), a nasal spray formulation of diazepam, for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.

Officers and directors

Ron Cohen M.D. President,Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Michael W. Rogers Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Lauren M. Sabella Executive Vice President - Commercial Development
Age: 53
Bio & Compensation  - Reuters
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Enrique J. Carrazana M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Andrew Asa Hindman Chief Business Development Officer
Bio & Compensation  - Reuters
David W. Lawrence Chief - Business Operations
Age: 56
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 50
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters